After telehealth startups recently lost the ability to sell exact copies of patented GLP-1 weight-loss drugs, some firms have begun turning to a different, less effective medication that has been on the market in the United States since 2010. Often considered a precursor to blockbuster products…
Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
